Literature DB >> 17630210

Genotype modulators of clinical severity in McArdle disease.

Juan C Rubio1, Félix Gómez-Gallego, Catalina Santiago, Inés García-Consuegra, Margarita Pérez, María I Barriopedro, Antoni L Andreu, Miguel A Martín, Joaquín Arenas, Alejandro Lucia.   

Abstract

The phenotypic manifestation of McArdle disease varies considerably from one individual to the next. The purpose of this study was to assess the possible association between the clinical severity of the disease, and each of the genotypes PYGM (R50X), ACE (I/D), AMPD1 (Q12X), PPARGC1A (G482S) and ACTN3 (R577X). We also assessed links between clinical disease severity and other potential phenotype modulators such as age or gender. McArdle disease was diagnosed in 99 patients of Spanish origin (60 male, 39 female; age range 8-81 years) by identifying the two mutant alleles of the PYGM gene. Disease severity was assessed using the grading scheme previously reported by Martinuzzi et al. [A. Martinuzzi, E. Sartori, M. Fanin, et al., Phenotype modulators in myophosphorylase deficiency, Ann. Neurol. 53 (2003) 497-502]. Significant correlation was observed (exact two-sided P<0.0001) between the number of D alleles of the ACE gene and the disease severity score. Rank-order correlation coefficients were 0.296 (95% CI: 0.169, 0.423) (Kendall's tau) and 0.345 (95% CI: 0.204, 0.486) (Somer's D). No significant relationships were detected between clinical severity and the remaining genotypes examined. Finally, disease severity was significantly worse in women with the disease. Our findings indicate that both ACE genotype and gender contribute to how McArdle disease manifests in an individual patient. The role of other candidate genes remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630210     DOI: 10.1016/j.neulet.2007.06.025

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

2.  The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications.

Authors:  Gisela Nogales-Gadea; Alfredo Santalla; Astrid Brull; Noemi de Luna; Alejandro Lucia; Tomàs Pinós
Journal:  J Inherit Metab Dis       Date:  2014-07-23       Impact factor: 4.982

3.  Identification of Potential Muscle Biomarkers in McArdle Disease: Insights from Muscle Proteome Analysis.

Authors:  Inés García-Consuegra; Sara Asensio-Peña; Rocío Garrido-Moraga; Tomàs Pinós; Cristina Domínguez-González; Alfredo Santalla; Gisela Nogales-Gadea; Pablo Serrano-Lorenzo; Antoni L Andreu; Joaquín Arenas; José L Zugaza; Alejandro Lucia; Miguel A Martín
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

Review 4.  Therapeutic options in other metabolic myopathies.

Authors:  Matthias Vorgerd
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

5.  ACTN3 genotype, athletic status, and life course physical capability: meta-analysis of the published literature and findings from nine studies.

Authors:  Tamuno Alfred; Yoav Ben-Shlomo; Rachel Cooper; Rebecca Hardy; Cyrus Cooper; Ian J Deary; David Gunnell; Sarah E Harris; Meena Kumari; Richard M Martin; Colin N Moran; Yannis P Pitsiladis; Susan M Ring; Avan Aihie Sayer; George Davey Smith; John M Starr; Diana Kuh; Ian N M Day
Journal:  Hum Mutat       Date:  2011-07-20       Impact factor: 4.878

6.  The cyclic nucleotide cGMP is involved in plant hormone signalling and alters phosphorylation of Arabidopsis thaliana root proteins.

Authors:  Jean Charles Isner; Thomas Nühse; Frans J M Maathuis
Journal:  J Exp Bot       Date:  2012-02-15       Impact factor: 6.992

7.  Genotypic and phenotypic features of all Spanish patients with McArdle disease: a 2016 update.

Authors:  Alfredo Santalla; Gisela Nogales-Gadea; Alberto Blázquez Encinar; Irene Vieitez; Adrian González-Quintana; Pablo Serrano-Lorenzo; Inés García Consuegra; Sara Asensio; Alfonsina Ballester-Lopez; Guillem Pintos-Morell; Jaume Coll-Cantí; Helios Pareja-Galeano; Jorge Díez-Bermejo; Margarita Pérez; Antoni L Andreu; Tomàs Pinós; Joaquín Arenas; Miguel A Martín; Alejandro Lucia
Journal:  BMC Genomics       Date:  2017-11-14       Impact factor: 3.969

8.  McArdle disease: a case report and review.

Authors:  Alberto Leite; Narciso Oliveira; Manuela Rocha
Journal:  Int Med Case Rep J       Date:  2012-01-20

9.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

10.  Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry).

Authors:  Tomàs Pinós; Antoni L Andreu; Claudio Bruno; Georgios M Hadjigeorgiou; Ronald G Haller; Pascal Laforêt; Alejandro Lucía; Miguel A Martín; Andrea Martinuzzi; Carmen Navarro; Piraye Oflazer; Jean Pouget; Ros Quinlivan; Sabrina Sacconi; Renata S Scalco; Antonio Toscano; John Vissing; Matthias Vorgerd; Andrew Wakelin; Ramon Martí
Journal:  Orphanet J Rare Dis       Date:  2020-10-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.